Portal de Periódicos da CAPES

The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting froml-dopa

2000; Wiley; Volume: 15; Issue: 5 Linguagem: Inglês

10.1002/1531-8257(200009)15

1531-8257

Hasmet A. Hana asi, G�l�st� Kaptano lu, H�seyin A. Sahin, Murat Emre,

Genetic Neurodegenerative Diseases

Movement DisordersVolume 15, Issue 5 p. 1016-1017 Clinical/Scientific Notes The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from l-dopa Hasmet A. Hanaḡasi MD, Hasmet A. Hanaḡasi MD Istanbul University, Istanbul Medical Faculty, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Capa, Istanbul, TurkeySearch for more papers by this authorGülüstü Kaptanoǧlu MD, Gülüstü Kaptanoǧlu MD Istanbul University, Istanbul Medical Faculty, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Capa, Istanbul, TurkeySearch for more papers by this authorHüseyin A. Sahin MD, Hüseyin A. Sahin MD Istanbul University, Istanbul Medical Faculty, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Capa, Istanbul, TurkeySearch for more papers by this authorMurat Emre MD, Corresponding Author Murat Emre MD Istanbul University, Istanbul Medical Faculty, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Capa, Istanbul, TurkeyIstanbul University, Istanbul Medical School, Department of Neurology, 34390 Capa/Istanbul, TurkeySearch for more papers by this author Hasmet A. Hanaḡasi MD, Hasmet A. Hanaḡasi MD Istanbul University, Istanbul Medical Faculty, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Capa, Istanbul, TurkeySearch for more papers by this authorGülüstü Kaptanoǧlu MD, Gülüstü Kaptanoǧlu MD Istanbul University, Istanbul Medical Faculty, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Capa, Istanbul, TurkeySearch for more papers by this authorHüseyin A. Sahin MD, Hüseyin A. Sahin MD Istanbul University, Istanbul Medical Faculty, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Capa, Istanbul, TurkeySearch for more papers by this authorMurat Emre MD, Corresponding Author Murat Emre MD Istanbul University, Istanbul Medical Faculty, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Capa, Istanbul, TurkeyIstanbul University, Istanbul Medical School, Department of Neurology, 34390 Capa/Istanbul, TurkeySearch for more papers by this author First published: 23 January 2001 https://doi.org/10.1002/1531-8257(200009)15:5 3.0.CO;2-JCitations: 21AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Papa SM, Chase TM. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996; 39: 574–578. 2Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989; 166: 591–592. 3Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P. Memantine displaces [3H] MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989; 166: 589–590. 4Schneider E, Fischer PA, Clemens R, Balzereit F, Fünfgeld EW, Haase HJ. Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study. Dtsch Med Wochenschr 1984; 109: 987–990. 5Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992; 4: 277–282. 6Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442. 7Verhagen ML, Del Dotto P, Munckhof PVD, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323–1326. 8Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvez Jimenez N. New use for an old drug: amantadine benefits levodopa-induced dyskinesia [Letter]. Mov Disord 1998; 13: 851. 9Verhagen ML, Blanchet PJ, Mouradian MM, Chase TN. Dextromethorphan and levodopa combination therapy in parkinsonian patients with response fluctuations [Abstract]. Mov Disord 1996; 11: 184. 10Blanchet PJ, Verhagen ML, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996; 11: 580–581. 11Spanagel R, Eilbacher B, Wilke R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat—a pharmacokinetic microdialysis study. Eur J Pharmacol 1994; 262: 21–26. 12Lupp A, Lücking CH, Koch R, Jaskisch R, Feuerstein TJ. Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 1992; 263: 717–724. 13Fischer PA, Jacobi P, Schneider E, Schönberger B. Effects of intravenous administration of memantine in parkinsonian patients. Arzneimittelforschung 1977; 27: 1487–1489. 14Weller M, Finiels-Marlier F, Paul SM. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 1993; 613: 143–148. 15Chen HS, Pellegrini JW, Aggarwal SK, et al. Open channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage agonist NMDA receptor-mediated neurotoxicity. J Neurosci 1992; 12: 4427–4436. 16Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Kristhal OA. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor anatagonistic effects of amantadine and memantine. Eur J Neurosci 1996; 8: 446–454. Citing Literature Volume15, Issue5September 2000Pages 1016-1017 ReferencesRelatedInformation